Prostate Cancer clinical trials
Showing 401–450 of 735 active trials. Describe your situation to see which ones you may be eligible for.
- Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
- A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
- Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- PSMA PET Combined With MRI for the Detection of PCa
- Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
- A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
- A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
- Zanzalintinib in Men With Aggressive Variant Prostate Cancer
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
- Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
- Study of How People Make Decisions About Prostate Cancer Risk
- Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide
- Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
- MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
- HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Water Vapor Ablation for Prostate Cancer: Long-Term Registry
- Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
- CUIMC Focal Therapy Registry
- Mechanisms of Resistance to PSMA Radioligand Therapy
- Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
- Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
- A Prospective Clinical Trial Evaluating PROSTest, a Blood-Based Molecular Assay, for Risk Stratification and Biopsy Decision Support in Men With Suspected Prostate Cancer
- A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Circulating Tumor DNA in High Risk Localized Prostate Cancer
- Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
- PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
- Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer
- Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
- SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
- Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
- COMPASS Study for Metastatic Castration-resistant Prostate Cancer
- Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
- Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
- Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
- Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
- Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
- Prostate Tissue BioBank
- ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
- iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men
- Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
- SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
- Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
- Real World Prostate Cancer Registry
- Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
- Focal Therapy for Localized Prostate Cancer
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.